Skip to main content
Premium Trial:

Request an Annual Quote

Agilent to Sell $750M in Notes

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies today said that it would offer $750 million worth of senior notes through two offerings.

The firm has not filed a final prospectus yet on the offerings. However, in a statement, Agilent said that it would use the proceeds to satisfy, in part, the financing obligation of Agilent Technologies World Trade, the subsidiary that acquired Varian for $1.5 billion in May.

Fitch Ratings placed a 'BBB' rating on the proposed notes offering.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.